ALNOV NOVACYT LONG
LONG TERM ANALISIS
It is at an important support in the long term and will reach significant resistance.
In Spain on 3/05/2022
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.5130 EUR
−49.33 M EUR
23.19 M EUR
70.48 M
About Novacyt SAS
Sector
Industry
CEO
Lyn Dafydd Rees
Website
Headquarters
Le Vésinet
Founded
2016
ISIN
FR0010397232
FIGI
BBG003CDTG68
IPO date
Oct 12, 2012
IPO offer price
10.50 USD
Novacyt SAS is a diagnostics company, which engages in the business of developing, producing, and selling vitro and molecular diagnostic tests and products for a wide range of infectious diseases. It operates through the following segments: Primer Design, IT-IS International, and Corporate. The Primer Design segment focuses on the activities of Primer Design Ltd, which is a designer, manufacturer, and marketer of molecular real-time qPCR testing devices and reagents. The IT-IS International segment is involved in IT-IS International Ltd, a diagnostic instrument development and manufacturing company specializing in the development of PCR devices for the life sciences and food testing industry. The Corporate segment includes group central and corporate costs. The company was founded by Eric Peltier, Gerald Ulrich, and Jean-Pierre Crinelli on July 3, 2006 and is headquartered in Velizy-Villacoublay, France.
Related stocks
Novacyt ALNOV They have at their disposal the technical analysis of Novacyt, it has great bullish potential, they have marked resistance and support.
I hope it will help you.
Sincerely, L.E.D. In Spain on 01/20/2022
Novacyt ALNOV They have marked the supports and resistances of ALNOV .
It has great upside potential, key level reaching $ 5
Last Friday news Clinical diagnostics specialist Novacyt announced on Friday thatots ‘genesig’ Covid-19 real-time PCR test has been approved in the UK. Great news and great upside potential
Novacyt ALNOV They have marked the supports and resistances of ALNOV.
It has great upside potential, key level reaching $ 5
Last Friday news Clinical diagnostics specialist Novacyt announced on Friday thatots ‘genesig’ Covid-19 real-time PCR test has been approved in the UK.
I send you a cordial greeting, Merry
Novacyt ALNOV Graham Mullis, CEO of the Novacyt Group, commented:
“Novacyt continues to process COVID-19 tests for current and future demand. We continue to ensure that innovation is at the center of our strategy and that our growing portfolio of COVID-19 tests is available to clients in private and public health
Novacyt NCTY what a pump !As you can see from the chart Novacyt had a massive volume inflow in the last 2 days even because of the very good news regarding the uk gov that accepted different NCTY covid tests and even because of the news of the new covid variant.
If you check my previous analysis I was waiting for a reversal
NCYT possible reversal pattern . I'm still bullish on this group,
I believe that the price will soon touch the support at 200 and get some high volume in and reverse the pattern getting back at some point to 500 zone.
( feel free to comment , I've just started to analise the graphs, any suggestions or critics are really apprecia
ALNOV Novacyt Graham Mullis, Group CEO of Novacyt, commented:
“Novacyt is continuing to address COVID-19 testing for both current and future demand. We continue to ensure that innovation is at the centre of our strategy and that our growing portfolio of COVID-19 tests are available to customers in both private an
ALNOV NOVACYT Novacyt big fall today, don't worry medium long term still hasn't broken level but keep an eye out for volatility next week we recommend that you buy if you can to the level you think is appropriate, it is a company that in the medium term has high expectations L.E.D Capital Management has investmen
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ALNOV is 0.4355 EUR — it has decreased by −1.14% in the past 24 hours. Watch Novacyt SAS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange Novacyt SAS stocks are traded under the ticker ALNOV.
ALNOV stock has fallen by −3.22% compared to the previous week, the month change is a −6.34% fall, over the last year Novacyt SAS has showed a −28.61% decrease.
We've gathered analysts' opinions on Novacyt SAS future price: according to them, ALNOV price has a max estimate of 0.74 EUR and a min estimate of 0.74 EUR. Watch ALNOV chart and read a more detailed Novacyt SAS stock forecast: see what analysts think of Novacyt SAS and suggest that you do with its stocks.
ALNOV reached its all-time high on Oct 26, 2020 with the price of 13.9600 EUR, and its all-time low was 0.0610 EUR and was reached on Oct 23, 2019. View more price dynamics on ALNOV chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ALNOV stock is 1.72% volatile and has beta coefficient of 0.19. Track Novacyt SAS stock price on the chart and check out the list of the most volatile stocks — is Novacyt SAS there?
Today Novacyt SAS has the market capitalization of 30.76 M, it has decreased by −1.11% over the last week.
Yes, you can track Novacyt SAS financials in yearly and quarterly reports right on TradingView.
Novacyt SAS is going to release the next earnings report on Apr 23, 2026. Keep track of upcoming events with our Earnings Calendar.
ALNOV net income for the last half-year is −7.53 M EUR, while the previous report showed −28.69 M EUR of net income which accounts for 73.75% change. Track more Novacyt SAS financial stats to get the full picture.
No, ALNOV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novacyt SAS EBITDA is −9.17 M EUR, and current EBITDA margin is −45.88%. See more stats in Novacyt SAS financial statements.
Like other stocks, ALNOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novacyt SAS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novacyt SAS technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novacyt SAS stock shows the sell signal. See more of Novacyt SAS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.